HQH (abrdn Healthcare Investors) Research & Development: $0.0 Mil (TTM As of Mar. 2026)


HQH abrdn Healthcare Investors HQH
40 GF Score
Price $21.63
GF Value $50.26
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is abrdn Healthcare Investors Research & Development?

abrdn Healthcare Investors HQH +1.93% 40 Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus rates HQH with a GF Score™ of 40/100 and a GF Value™ of $50.26 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. abrdn Healthcare Investors's Research & Development for the six months ended in Mar. 2026 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

abrdn Healthcare Investors  (NYSE:HQH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

abrdn Healthcare Investors Research & Development Related Terms

abrdn Healthcare Investors Research & Development Historical Data

* Premium members only.

The historical data trend for abrdn Healthcare Investors's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Healthcare Investors Research & Development Chart

abrdn Healthcare Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

abrdn Healthcare Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HQH
40GF Score
abrdn Healthcare Investors HQH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

abrdn Healthcare Investors Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.0 Mil mean?
abrdn Healthcare Investors (HQH) has a Research & Development of $0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on abrdn Healthcare Investors and its competitors.
Is abrdn Healthcare Investors' Research & Development too high?
abrdn Healthcare Investors' current Research & Development is $0.0 Mil. Overall, abrdn Healthcare Investors has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does abrdn Healthcare Investors' Research & Development compare to FPF and AOD?
abrdn Healthcare Investors' Research & Development of $0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on abrdn Healthcare Investors and its competitors. abrdn Healthcare Investors's current Research & Development is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Healthcare Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Healthcare Investors (HQH) is currently considered Possible Value Trap. The stock's GF Value™ is $50.26, compared to a current price of $21.63 — trading 57% below its estimated fair value. The current Research & Development is $0.0 Mil. abrdn Healthcare Investors' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For abrdn Healthcare Investors (HQH), the current Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Healthcare Investors (HQH) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Healthcare Investors stock appears to be undervalued. The current stock price of $21.63 is trading 57% below its estimated GF Value™ of $50.26. GuruFocus considers abrdn Healthcare Investors to be Possible Value Trap.

Key valuation signals for HQH:

  • Research & Development: $0.0 Mil
  • GF Value™: $50.26 vs. price of $21.63 (57% below fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the HQH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Healthcare Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
40GF Score

Get the complete analysis for HQH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.63
Price
$50.26
GF Value